CAI vs GS · rev $812.0M vs P/E 20, rev $37.56B
Caris Life Sciences, Inc. Common Stock (CAI) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
CAI currently screens at market cap $5.22B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CAI and GS stock pages for the full models.
Not investment advice.